Milestone Payments for Sample Clauses
Milestone Payments for. In further consideration of the license granted by Scynexis under Article 2 of this Agreement, upon [*], Elanco shall make a one-time payment in the sum of (i) [*] for a Product that contains an Active Ingredient which is [*], within [*] of attainment of such milestone; or (ii) [*] for any Product contains an Active Ingredient which is [*], within [*] of attainment of such milestone. For the sake of clarity, the milestone payment listed above is payable only once per Elanco Compound.
Milestone Payments for. [*]. If BMS is diligently developing and paying milestones to EPC under Section 7.2(a) [*], the payments otherwise to be made to EPC under Sections 7.2(a) for [*] shall be [*] such [*] the [*] in [*], in which case BMS shall pay EPC [*] any such [*] in [*] within [*] of the [*] such [*]; provided, however, that if this Agreement terminates before such [*], then BMS shall [*] pay EPC the [*]. If [*] the [*] or [*], then BMS shall only pay milestones [*] for the events that [*] the [*] such [*]; however, if a [*], then BMS shall pay the milestones [*] a [*] have been paid [*]. For clarity, the Parties agree that [*] shall [*], [*], or [*] of the [*] the [*].
Milestone Payments for. [ * ]. If BMS is diligently developing and paying milestones to Exelixis under Section 7.2(a) [ * ], the payments otherwise to be made to Exelixis under Sections 7.2(a) for [ * ] shall be [ * ] such [ * ] the [ * ] in [ * ], in which case BMS shall pay Exelixis [ * ] any such [ * ] in [ * ] within [ * ] of the [ * ] such [ * ]; provided, however, that if this Agreement terminates before such [ * ], then BMS shall [ * ] pay Exelixis the [ * ]. If [ * ] the [ * ] [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. or [ * ], then BMS shall only pay milestones [ * ] for the events that [ * ] the [ * ] such [ * ]; however, if a [ * ], then BMS shall pay the milestones [ * ] a [ * ] have been paid [ * ]. For clarity, the Parties agree that [ * ] shall [ * ], [ * ], or [ * ] of the [ * ] the [ * ].
Milestone Payments for. [***].
(i) [***]. Promptly following the completion of the analysis of the secondary end point of the [***], Licensor shall provide to Licensee a complete data package therefor, and such other information as Licensee may reasonably request in connection with its evaluation of such data. Within [***] days after receipt of all such data and information, the Parties shall endeavor to reach agreement as to whether such Clinical Data indicates that the [***] were met. If the Parties cannot agree as to whether the [***] were met, then the dispute shall be resolved pursuant to Section 13.6. If it is determined (by the Parties or pursuant to Section 13.6) that the [***] were met, then no later than [***] days following such determination, Licensee shall pay Licensor a milestone payment equal to [***]. Such payment shall be noncreditable against any other payments due hereunder.
(ii) [***]. No later than [***] days following Licensor’s notification to Licensee that it has enrolled at least [***] patients at sites in [***] combined for the [***], Licensee shall pay Licensor a milestone payment equal to [***] Dollars ($[***]). Such payment shall be noncreditable against any other payments due hereunder.
(iii) [***]. Promptly following the completion of the [***], Licensor shall provide to Licensee a complete data package therefor. Within [***] days after receipt of all such data and information, the Parties shall endeavor to reach agreement as to whether such Clinical Data indicates that the [***] were met. If the Parties cannot agree as to whether the [***] were met, then the dispute shall be resolved pursuant to Section 13.6. If it is determined (by the Parties or pursuant to Section 13.6) that the [***] were met, then no later than
Milestone Payments for. For the first occurrence of a milestone below achieved by an *** where ***leading to in vivo testing as set forth in Section 3.2 (a) (ii) and not subject to Section 4.4, AURORA, or a Third Party Client who separately contracts with SIDDCO in accordance with the terms set forth in Section 3.2 (a) (ii), ***the amounts set forth below within ***days following ***:
(a) In Vivo Testing. A fee of ***upon initiation of in vivo testing for good laboratory practice toxicology.
Milestone Payments for. [***]. No milestone payments shall be payable with respect to: (i) any Licensed Product [***], or (ii) any Licensed Product [***].
Milestone Payments for. 2.3.1 Standard Services shall be fixed prices calculated from the relevant Standard Service Unit Prices; and
2.3.2 Bespoke Services shall be fixed prices calculated from the relevant Bespoke Service Unit Prices.